Autres langues Apellis Pharmaceuticals, Inc.

Actions

APLS

US03753U1060

Temps Différé Nasdaq Autres places de cotation 21:54:50 30/04/2024			Varia. 5j.	Varia. 1 janv.
44,47 ^USD	-7,04 %		-8,35 %	-25,41 %

29/04	APELLIS PHARMACEUTICALS, INC. : Mizuho Securities toujours neutre sur le dossier	ZM
26/04	Apellis Pharmaceuticals déclare que l'EMA déplace la demande de pegcetacoplan à la dernière phase de l'évaluation initiale	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	26/04
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)	26/04
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	26/04
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	23/04
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	09/04
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	01/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21/03
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20/03
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	14/03
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11/03
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	07/03
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	05/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27/02
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Apellis Pharmaceuticals, Inc.

Actions

APLS

US03753U1060

Autres langues

Filtres